Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 7
Submit an article Journal homepage
122
Views
6
CrossRef citations to date
0
Altmetric
Review

Economic assessment on the management of chronic lymphocytic leukaemia

Kim M Goor University Medical Centre Rotterdam, Erasmus MC, Institute for Medical Technology Assessment, PO Box 1738, 3000 DR Rotterdam, The Netherlands. [email protected]
,
M Ronald Schaafsma Medisch Spectrum Twente, Department of Haematology, PO Box 50000, 7500 KA Enschede, The Netherlands
,
Peter C Huijgens VU University Medical Center, Department of Haematology, PO Box 7057, 1007 MB Amsterdam, The Netherlands
&
Michel van Agthoven University Medical Centre Rotterdam, Erasmus MC, Institute for Medical Technology Assessment, PO Box 1738, 3000 DR Rotterdam, The Netherlands
Pages 1179-1189 | Published online: 15 Jun 2005

Bibliography

  • VISSER O, SIESLING S, DUCK JE: Incidence of cancer in the Netherlands 1999/2000. Vereniging van Integrale Kankercentra, Utrecht, The Netherlands (2003).
  • BINET JL, AUQUIER A, DIGHIERO G et al.: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer (1981) 48(1):198–206.
  • RAI KR, SAWITSKY A, CRONKITE EP, CHANANA AD, LEVY RN, PASTERNACK BS: Clinical staging of chronic lymphocytic leukemia. Blood (1975) 46(2):219–234.
  • DAMLE RN, WASIL T, FATS F et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 94(6):1840–1847.
  • HAMBLIN TJ, DAVIS Z, GARDINER A, OSCIER DG, STEVENSON FK: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood (1999) 94(6):1848–1854.
  • ROZMAN C, MONTSERRAT E: Chronic lymphocytic leukemia. N Engl. J. Med. (1995) 333(16):1052–1057.
  • CHESON BD, BENNETT JM, GREVER M et al.: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 87(12):4990–4997.
  • DUTCH WORKING GROUP IN HAEMATO-ONCOLOGY (HOVON), INSTITUTE FOR MEDICAL TECHNOLOGY ASSESSMENT: Guideline Non-Hodgkin's Lymphoma (Dutch) Van Zuiden Communications BV, Alphen aan de Rijn (2004). A clear overview of the current standard practice in CLL in The Netherlands.
  • FLINN I, KUMM E, GREVER M et al.: Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup Trial E2997. Blood (2004) 104(11).
  • MELTZER MI: Introduction to health economics for physicians. Lancet (2001) 358(9286):993–998.
  • GARRISON L, TOWSE A: The drug budget silo mentality in Europe: an overview. Value Health (2003) 6\(Suppl. 1):S1–59.
  • VAN AGTHOVEN M, UYL-DE GROOT CA, SONNEVELD P, HAGENBEEK A: Economic assessment in the management of non-Hodgkin's lymphoma. Expert Opin. Pharmacother. (2004) 5(12):2529–2548.
  • DRUMMOND MF, O'BRIEN B, STODDART GL, TORRANCE GW: Methods for the economic evaluation of health care programmes. Oxford University Press, New York, NY, USA (1997).
  • GOLD MR, SIEGEL JE, RUSSELL LB: Cost-effectiveness in health and medicine. Oxford University Press, New York, NY, USA (1996).
  • ADAM T, KOOPMANSCHAP MA, EVANS DB: Cost-effectiveness analysis: can we reduce variability in costing methods? Int. j TechnoL Assess. Health Care (2003) 19(2):407–420. Identifies sources of variation in cost-effectiveness analyses and what can be done to circumvent these.
  • BORNHAUSER M, THIEDE C, SCHULER U et al.: Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant. (2000) 26(2):119–125.
  • BOSANQUET AG, BURLTON AR, BELL PB, HARRIS AL: Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP. Br. J. Cancer (1997) 76(4):511–518.
  • BOSANQUET AG, JOHNSON SA, RICHARDS SM: Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Br. J. Haematol. (1999) 106(1):71–77.
  • BOSANQUET AG, MCCANN SR, CROTTY GM, MILLS MJ, CATOVSKY D: Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol (1995) 93(2-4):73–79.
  • CHHIENG DC, CANGIARELLA JF, COHEN JM: Fine-needle aspiration cytology of lymphoproliferative lesions involving the major salivary glands. Am. J. Clin. Pathol (2000) 113(4):563–571.
  • CUTLER C, GIRI S, JEYAPALAN S, PANIAGUA D, VISWANATHAN A, ANTIN JH: Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. Clin. Oncol (2001) 19(16):3685–3691.
  • DICATO M, CHAPEL H, GAMM H et al.: Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review. Cancer (1991) 68(6 Suppl.):1437–1439.
  • GLIMELIUS B, BERGH J, BRANDT L et al.: The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types-summary and conclusions. Acta Oncol. (2001) 40(2-3):135–154.
  • ITALA M, HELENIUS H, NIKOSKELAINEN J, REMES K: Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur. J. Haematol (1992) 48(5):266–270.
  • JOHNSON SA: Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies. Clin. Pharmacoki net. (2000) 39(1):5–26.
  • JOHNSON SA: Nucleoside analogues in the treatment of haematological malignancies. Expert Opin. Pharmacother. (2001) 2(6):929–943.
  • JONES-GRIZZLE AJ, BOOTMAN JL: Pharmacoeconomics of genetically engineered drugs. Pharmacoeconomics (1992) 1(1):45–53.
  • MAGRATH I: Bone marrow transplantation for leukaemia: a lame stalking horse for use of high-technology medical care. Lancet (1995) 345(8950):601–602.
  • MASON JM, DRUMMOND MF, BOSANQUET AG, SHELDON TA: The DiSC assay. A cost-effective guide to treatment for chronic lymphocytic leukemia? Int. J. Technol Assess. Health Care (1999) 15(1):173–184.
  • MOLICA S, MUSTO P, CHIURAZZI F et al.: Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica (1996) 81(2):121–126.
  • OSCIER DG, MATUTES E, COPPLESTONE A et al.: Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12. Br. J. Haematol (1997) 98(4):934–939.
  • O'BRIEN S, KANTARJIAN H, BERAN M et al.: Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia (1997) 11(10):1631–1635.
  • WASELENKO JK, FLYNN JM, BYRD JC: Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized studies has arrived. Semin. Oncol (1999) 26(1):48–61.
  • WATERS TM, BENNETT CL, PAJEAU TS et al.: Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? Bone Marrow Transplant. (1998) 21(7):641–650.
  • WINSTON DJ, ANTIN JH, WOLFF SN et al.: A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant. (2001) 28(2):187–196.
  • CLL TRIALISTS' COLLABORATIVE GROUP: Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J. Natl. Cancer Inst. (1999) 91(10):861–868.
  • LUCE BR, SINGER JW, WESCHLER JM et al.: Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial. Pharmacoeconomics (1994) 6(1):42–48.
  • BELLIDO M, TOBIAS A, BRUNET S, SIERRA J: Bone marrow and peripheral blood stem cell transplantation in adult patients in first remission. Cochrane Database Syst. Rev. (2003) (1):CD004268.
  • MISHRA V, VAALER S, BRINCH L: A prospective cost evaluation related to allogeneic haemopoietic stem cell transplantation including pretransplant procedures, transplantation and 1 year follow-up procedures. Bone Marrow Transplant. (2001) 28(12):1111–1116.
  • RUIZ-ARGUELLES GJ, GOMEZ-ALMAGUER D, RUIZ-ARGUELLES A, GONZALEZ-LLANO O, CANTU OG, JAIME-PEREZ JC: Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. Am. J. Hematol (2001) 66(4):241–244.
  • VEENSTRA DL, HIGASHI MK, PHILLIPS KA: Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. (2000) 2(3):E29.
  • BLAISE D, KUENTZ M, FORTANIER C et al.: Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. Clin. Oncol (2000) 18(3):537–546.
  • DUNN CJ, GOA KL: Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs (2000) 59(3):681–717.
  • GOMEZ-ALMAGUER D, RUIZ-ARGUELLES GJ, RUIZ-ARGUELLES A, GONZALEZ-LLANO O, CANTU OE, HERNANDEZ NE: Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplant. (2000) 25(2):131–133.
  • RUIZ-ARGUELLES GJ, LOBATO-MENDIZABAL E, RUIZ-ARGUELLES A, PEREZ-ROMANO B, ARIZPE-BRAVO D, MARIN-LOPEZ A: Non-cryopreserved unmanipulated hematopoietic peripheral blood stem cell autotransplant program: long-term results. Arch. Med. Res. (1999) 30(5):380–384.
  • HAGGLUND H, RINGDEN O, OMAN S, REMBERGER M, CARLENS S, MATTSSON J: A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant. (1999) 24(8):831–836.
  • ISBISTER JP: Cytapheresis: the first 25 years. Ther. Apher. (1997) 1(1):17–21.
  • OERTEL MD: Anagrelide, a selective thrombocytopenic agent. Am. J. Health Syst. Pharm. (1998) 55(19):1979–1986.
  • RICHARDSON R, WADDINGTON C: Allocating resources: community involvement is not easy. Int. J. Health Plann. Manage. (1996) 11(4):307–315.
  • TYNELL E, ANDERSSON S, LITHANDER E et al.: Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis. Br. Med. J. (1998) 316(7142):1417–1422.
  • AUL C, BOWEN DT, YOSHIDA Y: Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica (1998) 83(1):71–86.
  • HUBEL A: Parameters of cell freezing: implications for the cryopreservation of stem cells. Transfus. Med. Rev. (1997) 11(3):224–233.
  • DEWALD GW, JUNEAU AL, SCHAD CR, TEFFERI A: Cytogenetic and molecular genetic methods for diagnosis and treatment response in chronic granulocytic leukemia. Cancer Genet. Cytogenet. (1997) 94(1):59–66.
  • PERKINS D, BRENNAN S, CARSTAIRS K et al.: Regional cancer cytogenetics: a report on 1,143 diagnostic cases. Cancer. Genet. Cytogenet. (1997) 96(1):64–80.
  • WILLIAMS CD, LINCH DC: Interferon alfa-2a. Br. J. Hosp. Med. (1997) 57(9):436–439.
  • HOROWITZ HW, HOLMGREN D, SEITER K: Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leuk. Lymphoma (1996) 23(1-2):159–163.
  • FLYNN TN, KELSEY SM, HAZEL DL, GUEST JF: Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK. Pharmacoeconomics (1999) 16(5 Pt 2):543–550.
  • ROSSINI F, PIOLTELLI P, BOLIS S et al.: Ceftriaxone/amikacin versus ceftazidime/ amikacin as empirical therapy for fever in patients with haematological malignancy and severe granulocytopenia. Clinical and economic outcomes. Clin. Drug Investig. (1998) 15(5):425–433.
  • SCHAFFNER A, SCHAFFNER M: Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J. Infect. Dis. (1995) 172(4):1035–1041.
  • O'CONNOR AM, STACEY D, ENTWISTLE Vet al.: Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst. Rev. (2003) (2):CD001431.
  • BOHLIUS J, LANGENSIEPEN S, SCHWARZER G et al.: Erythropoietin for patients with malignant disease. Cochrane Database Syst. Rev. (2004) (3):CD003407.
  • BAUDUER F, COUSIN T, BOULAT O et al.: A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia. Leuk. Lymphoma (2001) 42(3):379–386.
  • BALTZ JK, MONTELLO MJ: Cladribine for the treatment of hematologic malignancies. Clin Pharm (1993) 12(11):805–813.
  • VENUTA F, RENDINA EA, PESCARMONA EO et al.: Ambulatory mediastinal biopsy for hematologic malignancies. Eur. j Cardiothorac. Surg. (1997) 11(2):218–221.
  • PESSION A, PRETE A, PAOLUCCI G: Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer. Chemotherapy (1997) 43(5):358–366.
  • CHRISTIAN MS, HOBERMAN AM, JOHNSON MD, BROWN WR, BUCCI TJ: Effect of dietary optimization on growth, survival, tumor incidences and clinical pathology parameters in CD Sprague-Dawley and Fischer-344 rats: a 104-week study. Drug Chem. ToxicoL (1998) 21(1):97–117.
  • BENNETT CL, STINSON TJ, LANE D, AMYLON M, LAND VJ, LAVER JH: Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med. Pediatr. OncoL (2000) 34(2):92–96.
  • ETTINGER LJ: Asparaginases: where do we go from here? J. Pediatr. Hematol. OncoL (1999) 21:3–5.
  • MASERA G, BAEZ F, BIONDI A et al.: North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua. Lancet (1998) 352(9144):1923–1926.
  • MARCHETTI M, BAROSI G, LIBERATO LN: Fludarabine for chronic lymphocytic leukemia. N Engl. J. Med. (2001) 344(15):1166–1167.
  • SCHROEDER SA: Rationing medical care-a comparative perspective. N Engl. J. Med (1994) 331(10:1089–1091.
  • COBBS LS, CLARK PA, BRUSA M: The million dollar question. Hastings Cent. Rep. (2000) 30(5):24.
  • ANALO HI, AKANMU AS, AKINSETE I, NJOKU OS, OKANY CC: Seroprevalence study of HTLV-1 and HIV infection in blood donors and patients with lymphoid malignancies in Lagos, Nigeria. Cent. Aft J. Med. (1998) 44(5):130–134.
  • WEEKS JC, TIERNEY MR,-WEINSTEIN MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl. J. Med. (1991) 325(2):81–86.
  • HANCOCK S, WAKE B, HYDE C: Fludarabine as first line therapy for chronic lymphocytic leukaemia. West Midlands Health Technology Assessment Collaboration (WMHTAC), Birmingham, UK (2002).
  • •Review of the costs and effectiveness of fludarabine as first-line treatment in CLL.
  • HYDE C, WAKE B, BRYAN S et aL: Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment. Health TechnoL Assess. (2002) 6(2):1–89.
  • •Review of the costs and effectiveness of fludarabine as second-line treatment in CLL.
  • BENNETT C, WATERS T, STINSON T et al.: Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. (1999) 24(5):555–560.
  • CANADIAN COORDINATING OFFICE FOR HEALTH TECHNOLOGY ASSESSMENT: Alemtuzumab for the treatment of B cell chronic lymphocytic leukemia. Canadian Coordinating Office for Health Technology, Ottowa, Canada (2004).
  • AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS INC: Alemtuzumab. Am. J. Health Syst. Pharm. (2001) 58(24):2372–2373.
  • NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE: Guidance in the use offludarabine for chronic lymphocytic leukaemia. National Institute for Clinical Excellence, London (2001).
  • SCHERING HEALTH CARE LIMITED: Appraisal of Fludara (fludarabine phosphate). Schering health care limited, (2000).
  • ROCHE: MabThera (rituximab) NICE submission. Achieving clinical excellence in the treatment of follicular lymphoma. Roche (2000).
  • FISCHER AJ: Fludarabine Annex: cost effectiveness. National institute for clinical excellence, London (2001).
  • •Comparison of study results with regard to the cost effectiveness of fludarabine in CLL.
  • BEST L: Fludarabine in the treatment of Chronic Lymphocytic Leukaemia. Wessex Institute of Public Health, Bristol, UK (1995).
  • THE FRENCH COOPERATIVE GROUP ON CHRONIC LYMPHOCYTIC LEUKEMIA: Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. Blood (1990) 75(7):1414–1421.
  • DIGHIERO G, MALOUM K, DESABLENS B et al.: Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N EngL J. Med. (1998) 338(21):1506–1514.
  • BRUGIATELLI M, JAKSIC B, PLANINC-PERAICA A et al.: Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: long-term results of a randomized trial. Eur. J. HaematoL (1995) 55(3):158–163.
  • JACOBS P, KING HS: A randomized prospective comparison of chemotherapy to total body irradiation as initial treatment for the indolent lymphoproliferative diseases. Blood (1987) 69(6):1642–1646.
  • SAVEN A: The Scripps Clinic experience with dadribine (2-CdA) in the treatment of chronic lymphocytic leukemia. Semin. HematoL (1996) 33(1 Suppl. 1):28–33.
  • TALLMAN MS, HAKIMIAN D: Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood (1995) 86(7):2463–2474.
  • MONTSERRAT E, VILLAMOR N, URBANO-ISPIZUA A, RIBERA JM, ROZMAN C: Alpha interferon in chronic lymphocytic leukaemia. Eur. j Cancer (1991) 27\(Suppl. 4):74–77.
  • PATENTED MEDICINE PRICES REVIEW BOARD: Report on new patented drug MAbCampath. Patented Medicine Prices Review Board, Ottawa, Canada (2004).
  • BRITISH MEDICAL ASSOCIATION AND ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN: British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, UK (2001).
  • NETTEN A, CURTIS L: Unit costs of health and social care 2000. Personal Social Services Research Unit, University of Kent, Canterbury, UK (2000).
  • SWEETENHAM J, HIEKE K, KERRIGAN M et al.: Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K. Br. J. HaematoL (1999) 106(1):47–54.
  • VAN AGTHOVEN M, SONNEVELD P, VERDONCK LF et al.: Cost determinants in aggressive non-Hodgkin's lymphoma. Haematologica (2005) 90:(5):661–671.
  • HEROLD M, HIEKE K: Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment. Value Health (2003) 6(2):167–174.
  • HEROLD M, HIEKE K: Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine. Eur. Health Econ. (2002) 3(3):166–172.
  • VAN AGTHOVEN M, VELLENGA E, FIBBE WE, KINGMA T, UYL-DE GROOT CA: Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease, a prospective randomised trial. Eur. J. Cancer (2001) 37(14):1781–1789.
  • VAN AGTHOVEN M, GROOT MT, VERDONCK LF et al.: Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant. (2002) 30(4):243–251.
  • SCHULMAN K, BURKE J, DRUMMOND M et al.: Resource costing for multinational neurologic clinical trials: methods and results. Health Econ. (1998) 7(7):629–638.

Websites

  • http://www.cancer.org/downloads/stt/ Estimated_New_Cancer_Cases_and_Death s by Sex for All Sites, US, 2005.pdf American Cancer Society: cancer facts and figures (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.